Pierre Fabre Medicament

Centre National De La Recherche Scientifique

El Bachir Kaloun

Michel Perez

Arnaud Marchand

Stéphane Poigny

Anna Kruczynski

Houcine Rahali

Rémi Rabot

Karim Bedjeguelal

Philippe Schmitt

Nicolas Rahier

Laurent Creancier

Frédéric Marion

Jean-Philippe Annereau

Patrice Mayer

Frédéric Lieby-Muller

Paola Barbara Arimondo

Serge Grisoni

Rachid Rahali

Christophe Long

Hugues Bienayme

Ludovic Halby

Yoann Menon

Emmanuel Fournier

Bruno Gomes

Philippe Schambel

Antoine Dumoulin

Pascaline Klein

Remi Rabot

Paola B Arimondo

Hugues Bienhayme

Eric Tam

The invention concerns a compound of the following formula (I) or a pharmaceutically acceptable salt or solvate thereof as well as a pharmaceutical composition containing such a compound, and the use of such a compound as a drug, notably as a DNMT inhibitor, in particular in the treatment of cancer. 

Hemi-synthetic trilobine analogs for use as a drug

The invention relates to compounds of the following general formula (I) in the form of one of the enantiomers thereof or a mixture of the enantiomers thereof, and the pharmaceutically acceptable salts and/or solvates thereof, especially for the use thereof as a medicament, more specifically in cancer treatment. The invention also relates to pharmaceutical compositions containing same and to the methods for the production thereof.

Flavagline derivatives

The present invention relates to a compound with the following formula (I): (I) or a salt and/or a pharmaceutically acceptable solvate thereof, in particular for use as a drug, in particular in the treatment of cancer, as well as to the pharmaceutical compositions that contain same and to the methods for preparing same.

Derivatives of macrocyclic N-aryl-tricyclopyrimidine-2-amine polyethers as inhibitors of FTL3 and JAK

The present invention relates to a compound of the following formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, notably for use as a drug, notably in the treatment of cancer, as well as pharmaceutical compositions containing such a compound and processes to prepare such a compound. 

Isoquinolinone derivatives useful in the treatment of cancer

The present invention relates to a compound of following formula (I) or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture, as well as pharmaceutical composition comprising such a compound, for use in the treatment of a cancer associated with the overexpression of at least one Trk protein. 

Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing Trk

The present invention relates to compounds of following general formula (I): and to the pharmaceutically acceptable salts of same, the tautomers of same, the stereoisomers or mixture of stereoisomers in any proportions of same, such as a mixture of enantiomers, notably a racemic mixture, as well as to methods for preparing same and uses of same, notably as an antineoplastic agent. 

Tri- and tetracyclic pyrazolo[3,4-B]pyridine compounds as antineoplastic agent

The present invention concerns compounds of following general formula (I): (Formula I) and their pharmaceutically acceptable salts, their method of preparation and their uses, notably as anticancer agent. 

Pyrazolopyridine derivatives as anticancer agent

The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; as well as to the use of same as a drug, notably intended for the treatment of cancer, inflammation and neurodegenerative diseases such as Alzheimer's disease; to the use of same as a kinase inhibitor; to the pharmaceutical compositions comprising same; and to methods for the preparation of same.

Substituted pyrazolo[3,4-b]pyridines as medicaments

Growing community of inventors

Roquettes, France

El Bachir Kaloun